Implementation of “coverage with evidence development” drug approval strategies found lacking

15 July 2019 - Lessons from early deployments in The Netherlands. ...

Read more →

The FDA disagrees with its own expert panels how often?

15 July 2019 - As the FDA grapples with rising pressure to approve new medicines more quickly, a new analysis ...

Read more →

Reforming the Orphan Drug Act for the 21st century

11 July 2019 - The pharmaceutical market has undergone radical changes, including markedly increased prices for rare-disease drugs.  ...

Read more →

Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods

10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...

Read more →

A Supreme Court ruling may have made it harder to get some info from the FDA

9 July 2019 - Anyone seeking certain information about a medicine from the FDA may have a harder time getting ...

Read more →

New committee brings diverse patient, family, and caregiver voices to CADTH

10 July 2019 - Following a nationwide call for nominations, CADTH is pleased to announce the membership of its new ...

Read more →

UK’s drug-buying agency CEO: Why we like to say ‘yes’

1 July 2019 - While more than 100 medicines sit on Pharmac's waiting list, some for 10 years, the UK's own ...

Read more →

NICE explores extending its use of data to inform its guidance

25 June 2019 - NICE has revised its earlier press release on the use of real world data to inform ...

Read more →

How to deal with the inevitable: generating real-world data and using real-world evidence for HTA purposes – from theory to action

14 June 2019 - Real-world evidence, derived from real-world data, is already used, to some extent, for health technology assessment purposes.  ...

Read more →

The Cancer Drugs Fund in practice and under the new framework

12 June 2019 - The Cancer Drugs Fund was established in 2010 to improve access to treatments not routinely available. ...

Read more →

Behind the scenes at the PBAC

11 June 2019 - Outgoing RACGP representative Rashmi Sharma pulls back the curtain after 10 years on the Pharmaceutical Benefits Advisory ...

Read more →

Australians’ lives have a price – a ‘quality-adjusted life year’ worth about $50,000

3 June 2019 - How much is your life worth? What would you pay to keep it? More importantly, what would ...

Read more →

Campaign wants patients to have more influence on PBS

3 June 2019 - Australian patients should be given greater say in the medicines that receive government reimbursement as consumers ...

Read more →

Use of real world data sources for Canadian drug pricing and reimbursement decisions: stakeholder views and lessons for other countries

29 May 2019 - Canada has a long history of the use of clinical evidence to support health care decision making.  ...

Read more →

Cost effectiveness analysis in the context of US commercial health insurance

29 May 2019 - Discussions of the cost effectiveness of medical services often are couched in the framework of a ...

Read more →